Icos critically regulates the expansion and function of inflammatory human th17 cells
AssigneeThe Trustees of the University of Pennsylvania
InventorsJames L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
Life of this patent
Estimating the term…
Abstract
The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
Claims24
A composition comprising a first agent that is capable of providing a primary activation signal to a T cell and a second agent that is capable of activating ICOS on said T cell.
2-6. (canceled)
9-13. (canceled)
A method for activating or stimulating a population of T cells, said method comprising:
- 1) providing a population of cells wherein at least a portion thereof comprises T cells;
- 2) contacting said population of cells with a composition comprising a first agent that is capable of providing a primary activation signal to said T cells and a second agent that is capable of activating ICOS on said T cells.
24-32. (canceled)
A method of immunotherapy comprising administering an ICOS stimulated T cell to a patient in need thereof.
(canceled)
Dependencies are inferred from the claim text.